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ABSTRACT 
Allergy to furred animals is a common affliction, where up to 20% of the population in affluent 
countries are sensitized to one or more pet allergens. Several causative allergens from an array of 
species have been identified, but there are still gaps in our knowledge. This complicates diagnosis and 
treatment of allergy to pets. Conventional methods rely on naturally derived allergen extracts, with 
poor characterization and lack of broadly accepted standards. Due to the nature of the extracts, some 
allergens could be missing or present in clinically non-significant concentrations. The aim of the thesis 
is to improve diagnostics by characterizing extracts and evaluating component based microarrays to 
conventional methods. Further, to identify new allergens as well as describe previously only partially 
characterized allergens, their distribution and properties. 
 
Paper I compares two multiplex microarray assays in allergy diagnostics to the standard methods 
ImmunoCAP and skin prick test with doctor’s diagnosis in a cohort of children with persistent asthma 
(n=71). The results showed that 75% of all children were sensitized to at least one allergen and that 
nearly half was multisensitized to three or more allergens. The accuracy of the methods was 
comparable, they all had a pair-wise concordance of 90% and above. However, the microarray assays 
contributed with positive IgE responses to new allergens not described in the diagnosis in almost half 
the patients (47%). The added value of microarray analysis in multisensitized patients is not to belittle.  
In paper II, an analysis of the content and composition of dog dander extracts for skin prick test is 
conducted. Results from five commercial manufacturers display a large variation, not only between 
the different suppliers, but also between batches albeit to a lesser extent. Anatomical location of the 
source material also differs, hair, dander and epithelia was analyzed. Two of the allergens were 
detected only at low amounts and patient sera sensitized to these failed to induce an allergic response 
to the extracts in a basophil activation test. Moreover, a population of dogs was investigated in regard 
to their allergen profile, also resulting in a substantial divergence between individuals. The 
heterogeneity of the extracts calls for better content characterization and standardization. Substandard 
quality could render flawed diagnosis and jeopardize patient safety. 
Paper III characterizes sensitization to horse allergens, where several allergens are only described 
partially, or analysis of IgE binding performed in a small cohort. We present sensitization data for four 
horse allergens including a novel protein, designated Equ c 7, with a prevalence of 38%. Equ c 7 is a 
homologue to the cat allergen Fel d 1, suggesting possible cross-reactivity. Further, we describe two 
forms of full-length Equ c 2 and the potential roles of isoforms. Here we contribute to the panel of 
horse allergens. Allergy to horse is less investigated than to other pets and likely more allergens await 
discovery.  
Aerodynamic properties of allergens are investigated in paper IV, where three dog allergens were 
sampled, however, only two could be detected. Particles associated with airborne allergen differed in 
size. Can f 1 was only detected on particles larger than 2.8 µm, diversely from Can f 4 which was 
found on particles of all sampled sizes >8.3-<0.34 µm. Smaller particles reach the small airways and 
are causative of inflammation and airway responsiveness. Different sampling methods also yielded 
different proportions of the allergens, indicating that they possess different airborne properties.  
To summarize, furred animals produce a wide array of allergens and there is a large individual 
variation in expression levels/profiles. This is mirrored in the extracts used for diagnosing allergy, 
where poor quality counteracts correct diagnosis. Characterization of novel allergens and production 
of recombinant equivalents could improve the accuracy of diagnostics and therapy.  
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1 INTRODUCTION 
As living beings, we are constantly under attack from pathogens, which require our 
physiology to reproduce and thrive. The downside for us is that our bodies are damaged in 
that process, sometimes unrepairable or worse even fatally. Thus a war is constantly being 
waged between us and invasive microorganisms. To that end, the immune system has 
evolved in an arms race, to help us gain the upper hand in survival. Unfortunately, sometimes 
the immune system mistakes a harmless object for a pathogen and responds accordingly. This 
may result in causing harm instead of protecting the body, manifesting diseases like 
autoimmunity and allergy. This thesis contributes with new insights regarding the allergens 
causing allergic disease to pets, their variability, properties and distribution, to improve 
diagnosis and treatment of allergy.   
1.1 THE IMMUNE SYSTEM 
1.1.1 The innate immune system 
The immune system constitutes two major parts, the innate and the adaptive immune system. 
The innate immune system, which is present at birth, includes the first line of defense with 
physical outer barriers such as the skin, mucosa and epithelial layers. Their role is to prevent 
entry into the body, but if damaged or compromised pathogens might penetrate. When that 
occurs, antimicrobial proteins, the complement system and innate immune cells are 
circulating to identify and neutralize the threat. The innate immune system is non-specific but 
responds quickly to pathogens or cell damage using pathogen-associated molecular patterns 
respectively damage-associated molecular patterns (PAMPs/DAMPs) (1). These receptors 
have a limited diversity, about 100 receptors have the ability to recognize around 1000 
antigens (2). But the antigens identified represent commonly distributed preserved essential 
features of pathogens, such as lipopolysaccharide of bacterial cell walls or double stranded 
RNA, frequent in viruses but foreign in humans. The PAMPs and DAMPs are found on cells 
associated with the innate immune response such as neutrophils, macrophages or NK-cells, 
but also on epithelial cells in the barriers. When a pathogen is identified, these cells try to 
eliminate the microorganism by phagocytosis, opsonization or cytotoxicity also causing 
inflammation (3). Secreting inflammatory mediators as chemokines and cytokines also helps 
signal to attract more immune cells to the site of infection and to appropriately activate them. 
Specialized antigen presenting cells (APCs) also express PAMP/DAMP receptors. In this 
way they constitute a bridge between the innate and the adaptive arm of the immune system, 
and dendritic cells for instance, have the ability to activate the adaptive immune system to get 
a tailored, more persistent response to the pathogen.   
1.1.2 The adaptive immune system 
The adaptive immunity takes longer to engage, but carries substantially more specificity. It 
also harbors a memory which increases the efficiency towards the same antigen following 
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repeating encounters (4). However, more recent research has shown an advanced interplay 
between the innate and the adaptive systems, where some cells perform functions or share 
characteristics attributed to both systems (5-8). The adaptive immune system requires 
multiple activation signals, including co-receptors and cytokines to upregulate and mature 
into effector cells. Innate immune cells engage and activate the adaptive cells, namely 
lymphocytes during an infection. Lymphocytes comprises of T and B cells, these cells have a 
much broader repertoire of antigen recognition through the T or B cell receptors (TCR/BCR), 
compared to the innate cells. However, each individual cell carries only one specificity, 
determined through hypervariable regions and somatic gene rearrangement. These features 
allow a vast array of possible combinations and specificities (9).  
1.1.3 T cells 
T cells are lymphocytes that are specialized for specific antigen recognition through the TCR 
and responsible for cell mediated immunity. All T cells display the surface marker CD3 
(cluster of differentiation), a co-receptor in conjunction with the TCR and ζ-chain forming 
the TCR complex. T cells are classified in two major groups depending on the presence of a 
second surface co-receptor, CD4 or CD8, giving them different capabilities and function. The 
CD8+ cells, or cytotoxic T cells, recognize major histocompatibility complex (MHC) class I 
molecules presented on all of the own body’s cells when infected with an intracellular 
pathogen. The MHC complexes are encoded in the human leukocyte antigen (HLA) genes, 
and are like the TCR/BCR, highly diverse. Together they represent most polymorphic genes 
in the genome, to provide a broad repertoire of specificity. When activated the CD8+ T cell 
kills off the infected cell, mainly through cell lysing mechanisms by releasing their granules 
containing perforin and granzymes.  
CD4+ T cells are called T helper cells due to their ability to activate and facilitate 
differentiation of other immune cells. The CD4+ T cell recognizes antigens presented on the 
MHC class II molecule of antigen presenting cells, which are extracellular foreign antigens 
digested and displayed as peptides on the surface of the APC. The activated CD4+ cell 
differentiate into an effector cell which produces cytokines to recruit and activate different 
target cells depending on the present microbe (2). To that end different subpopulations of 
CD4+ cells have evolved. TH1 type cells are characteristic of combating viruses and 
intracellular pathogens, macrophages have been shown to induce this pathway (10) as well as 
dendritic cells (11) through interleukin (IL)-12 and interferon gamma (IFNγ). The TH1 cells 
in turn produce more IFNγ and express the CD-40 ligand to enhance macrophages’ ability to 
kill ingested microorganisms. The TH2 pathway is initiated by IL-4 from mast cells or 
epithelial cells, in response to extracellular parasites (12). The typical cytokines produced by 
TH2 are IL-4 to continue the TH2 differentiation, IL-5 to recruit eosinophils for killing 
parasites and IL-13 to increase mucus secretion and contractions of smooth muscle (13). 
These cytokines also promote the alternative pathway of macrophages, to produce growth 
factors and stimulate fibrosis (14). TH17 cells differentiation occurs in response to bacterial or 
fungal infections, where dendritic cells secrete IL-1, IL-6, IL-23 and TGF-β (15). These cells 
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produce IL-17 and IL-22 (16) recruiting neutrophils and driving inflammation as well as 
repairing epithelia. Recent research has also linked them with the defense against intracellular 
bacteria (17). Further, additional subsets have been identified, e.g. TH22, which is a pro-
inflammatory lineage of T cells infiltrating the epidermis, producing IL-22 and TNF-α (18) 
and shown to assist in cutaneous immunity (19). TH9 is another subset of T helper cells, 
which have been implicated in contributing to allergic responses by secretion of IL-9. The 
cytokine, together with IL-4 stimulate B cells to produce IgE (20) and are necessary for mast 
cell amassment during inflammation (21). 
1.1.4 B cells 
B cells belong to the second class of lymphocytes, responsible for the humoral branch of the 
adaptive immune system, the major effector function being antibody production. In contrast 
to T cells, the antigen receptor immunoglobulin (Ig) can exist either as a membrane receptor 
(BCR) or in soluble form as an antibody. Both types share the same specificity on an 
individual cell. Another distinction between T and B cell receptors is that while the TCR 
recognizes peptides and linear epitopes, the immunoglobulin bind to the whole antigen and 
thus conformational epitopes (9). Two membrane bound Ig classes are expressed on naïve B-
cells, IgM and IgD. These receptors recognize and bind antigen, but need a second stimulus 
to cause activation. The mode of activation can either be T cell dependent if the antigen in 
question is a protein, or T cell independent during polysaccharide or lipid encounters where 
the repetitive antigens have the ability to cross-link adjacent Ig molecules or bind innate toll-
like receptors on the B-cell. The activated B cell undergoes clonal expansion and 
differentiation into either antibody producing plasma cells or memory B cells. The T cell 
dependent pathway also have the ability to induce class switching and affinity maturation to 
further tailor the response (22). The remaining three Ig classes are a result of isotype 
switching depending on the type of T cell help and the milieu.  
1.1.5 Antibodies 
Antibodies, the secreted form of immunoglobulin, consist of two variable regions, (fragment 
antigen binding, Fab) and a constant one (fragment crystallizable, Fc). The Fab portion of the 
antibody is highly diverse and can bind a vast array of antigens. Due to the rearrangement of 
the V(D)J domains of the genome this polymorphism is possible. Further specialization 
occurs by class-switch recombination and somatic hypermutation, where AID plays a vital 
role. AID is a single stranded DNA that causes mismatched DNA by deamination. When 
DNA repair systems removes the mismatch, mutations arises causing further diversity (23). 
The Fc region determines the isotype of the antibody and thus the function. The region bind 
receptors on cell surfaces eliciting a cellular response causing either up- or downregulation. 
Hence, Fc receptor signaling determines the immune response from the affected cells (24).  
The Ig isotype IgM is either expressed as a surface bound monomer or secreted as a pentamer 
during infections where it opsonizes pathogens (25). IgD can also be secreted as a soluble 
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form in blood serum. It’s role in immune responses is still unclear, but it is suggested to be 
involved in maintaining homeostasis (26). IgG can trigger up-regulation and activation of 
myeloid cells and some endothelial cells, facilitating phagocytosis, endocytosis and antibody-
dependent cellular cytotoxicity (ADCC). IgG can also opsonize pathogens to be recognized 
by NK-cells and destroyed. However, IgG can also bind to the inhibitory receptor FcγRIIb 
expressed on mast cells, basophils and monocytes to initiate a down-regulation of the cell 
(27). IgE is engaged in the defense against helminth infections and are pathologically 
associated with allergic diseases and asthma (28). IgE binds to the high affinity receptor 
FcεRI, present on mast cells, basophils, eosinophils and DC. Mast cells, the main expresser of 
FcεRI, become coated with antibodies when sensitized. Upon antigen interaction the cell 
degranulates releasing mediators toxic to parasites, causing inflammation. The antibody is 
also involved in IgE dependent phagocytosis as well as B-cell maturation and survival (29). 
Lastly, IgA is found in serum, but predominantly on mucosal surfaces and in secretions. IgA 
can act both pro-inflammatory, when binding an antigen forming an immune complex 
causing cytokine release, cytotoxicity and phagocytosis, and anti-inflammatory (30). The IgA 
immune complex can also pass though membranes via the polymeric transmembrane receptor 
pIgR, eliminating the pathogen from circulation and function as a way of clearing infections 
(31, 32). 
1.1.6 Immune dysregulation 
The immune system is highly effective in eradicating pathogens and keeping us healthy. The 
aptitude however comes at a price. Sometimes the immune system recognizes harmless 
molecules as threats or worse, the own self as foreign. Hereditary defects in the genome or 
mutations can also cause immune deficiencies. For example, defective T cell development 
can cause severe combined immunodeficiency (SCID), the individuals lacking functional T 
cells and generally having a low lymphocyte population. The condition causes critical 
infections and predisposes to early death (33). Loss of CD40 or CD40L due to mutations 
resulting in an inability of B-cells to undergo class-switch, causes hyper-IgM syndrome as 
well as a shortage of the other antibody isotypes. This manifests as recurrent bacterial 
infections, autoimmunity and malignancy (34). Hyper-IgE syndrome (HIES) patients have a 
defect in the transcription factor STAT3, critical for differentiation of T cells into TH17 cells 
and activation of innate lymphoid cells type 3 (ILC3). Absence of these cells causes a 
multitude of bacterial and fungal skin and pulmonary infections including eczema. The 
reason for the elevated IgE levels is not fully understood, however these patients lack a 
pronounced TH2 phenotype and the IgE is not allergen-specific, resulting in less allergic 
disease compared to atopic patients (35). Immune deficiencies can also be acquired from 
pathogen exposure. The retrovirus HIV causes acquired immune deficiency syndrome 
(AIDS), characterized by a depletion of CD4+ cells, eventually causing recurrent infections 
and malignancies, resulting in death if untreated (36).  
During lymphocyte development in the thymus and bone marrow, the cells undergo several 
selection steps to ensure that the naïve lymphocytes have the ability to identify foreign 
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antigens meanwhile discriminating self-antigens, thus inducing self-tolerance. When the 
immune system fails to distinguish one’s own antigens from those foreign, the result can lead 
to severe tissue damage manifesting as autoimmunity (37). T cell mediated autoimmunity 
includes for example diabetes type I where TH1 cells react towards pancreatic islet antigens 
on β-cells, destroying these resulting in lack of insulin production. Multiple sclerosis is 
another severe form of autoimmunity, where the autologous T cells attack the myelin sheaths 
of the central nervous system, creating plaques causing the myelin to dissolve and the nerve 
signals to diminish. Common symptoms are muscle weakness, ataxia, blindness and 
ultimately paralysis. Several autoantigens have been suggested as targets, myelin 
oligodendrocyte glycoprotein (MOG) being one of the first identified, but questioned more 
recently. However, advances are being made in detecting novel autoantigens and more 
sensitive methods are under development (38).  
Allergic disease is also a consequence of a dysfunctional immune response, in this instance 
hypersensitivity. The immune system mistakes a harmless molecule, for instance pollen or 
food, for a pathogenic one and responds accordingly causing harm to the body in the process. 
1.2 ALLERGY 
1.2.1 Hypersensitivity 
Clemens von Pirquet first defined allergy as the odd disposition of some people to respond 
with hypersensitive symptoms to specific substances in 1906 (39). Gell and Coombs, two 
British immunologists suggested in 1963 that there were four types of allergic reactions that 
was the result of hypersensitivity (40). They proposed a classification, despite lack of 
knowledge on immune mechanisms like T cell functions and cytokine repertoire at the time 
drafted, which was adopted for decades. The classical classification was defined as: 
Type I – Acute type, IgE mediated. When the antigen is recognized and bound by IgE 
antibodies on mast cells, IgE crosslinks causing degranulation and release of mediators 
instantaneously. 
Type II – Semi-delayed, antibody mediated. Autoreactive IgG recognizing host cell and 
opsonizes it. Cell is lysed by complement or antibody-dependent cellular cytotoxicity by NK 
cells. 
Type III – CIC mediated. Immune complexes are formed and deposited in tissues from 
abundant antigen bound to antibodies and complement. Causing inflammation and tissue 
damage. 
Type IV – Delayed-type, cell mediated. The antigen is presented by an APC to a T cell, 
activation occurs and cytokines are released. 
However, the validity for all types of hypersensitivity reactions have been debated as well as 
the lack of a more complex accurate description (41). A new revised classification was 
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proposed by Johansson et al, accepted by EEACI in 2001 (42) and by the World Allergy 
Organization in 2003 (43). The consensus of the current hypersensitivity classification is as 
follows:  
Non-allergic hypersensitivity 
Allergic hypersensitivity 
 IgE-mediated 
  Atopic 
  Non-atopic, e.g. insect sting, helminth infection, pharmaceutical,  
 Non IgE-mediated 
  T cell-mediated, e.g. celiac disease 
  Eosinophilic, e.g.  eosinophilic esophagitis 
  IgG-mediated, e.g. allergic alveolitis 
  Other 
1.2.2 IgE-mediated allergy 
We are constantly exposed to potential allergens from the environment. People with IgE-
mediated allergy respond to these allergens by producing IgE antibodies, referred to as 
sensitization. However, some people develop allergic disease and other do not. Hereditary 
predisposition to develop allergies is described as atopy (from Greek atopos, meaning out of 
place) (44). Having atopic parents increases the likelihood of the child to develop allergic 
disease (45, 46). Further, the gender of the child may influence the parental contribution to 
atopy. A higher risk of girls developing allergy has been shown to depend of maternal allergy 
and the same has been shown for boys and paternal allergy (47). Certain alleles, like a 
polymorphism of the 17q21 locus, have also been linked with high risk of developing asthma, 
which could be an explanation for the diverging results of the hygiene hypothesis and pet 
keeping (48). Mutations in filaggrin functionality also have an effect on risk of sensitization, 
but the outcome differs depending on the allergen and age of exposure (49). However, several 
factors influence the risk of developing allergy, besides the genes, and the cause is likely 
multifactorial (50).  
The hygiene hypothesis has long been a favored explanation for increased risk of 
sensitization. It was coined by Strachan in 1989, who observed that children growing up in 
larger families had a lower incidence of hay fever and eczema compared to children in 
smaller families (51). He postulated that the unhygienic contact with siblings or infected 
mother would explain the difference. Thus early exposure to microorganisms would provide 
protection against development of allergies and overly clean environments would be 
disadvantageous. Some later studies have supported the hypothesis (52), while others have 
shown more conflicting results depending on the pathogen exposure (53), where e.g. RSV 
infection in infancy seems to increase the risk for allergy (54, 55). However, growing up on a 
farm decreases the risk of developing allergies according to several studies (56-59). Living 
with cats and dogs during the first year of life also provide a protective effect against allergic 
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disease (60-62). The composition and diversity of the gut flora during infancy has proven to 
impact the risk of sensitization and asthma (63, 64), where T-regulatory cells are important 
for keeping homeostasis (65). Further, even later in life altered microbiota have been linked 
with inflammatory disease e.g. rheumatoid arthritis (66). The same is true for the airways, 
where an abundance of certain strains of Proteobacteria is linked with incidence of asthma 
(67) and Moraxella or Haemophilus infiltration associated with neutrophilia (68).  
1.2.3 Sensitization 
The first time an allergen is encountered in an atopic individual, sensitization occurs without 
symptoms. The allergen breaches the mucosal layers in the airways, gastrointestinal tract or 
penetrates disrupted epithelia in the skin, see figure 1. House dust mite (HDM) allergen even 
have the ability to disrupt tight junctions using protease activity (69). Dendritic cells in the 
tissue capture and process the allergen, causing the DC to mature and migrate to the regional 
lymph node. In the lymph node the DC presents the processed allergen peptides to naïve T 
cells using the MHC class II molecule. If recognized, depending on the milieu and presence 
of IL-4 from mast cells or epithelial cells, the naïve T cell will differentiate into an effector 
TH2 cell. The TH2 cells start to produce more IL-4 and IL-13, and activate B cells and 
phagocytes by engaging their CD40 receptor using the CD40 ligand and CD80/86 with CD28 
(70). The B cell undergoes class switch and starts producing IgE, and with help of resident T 
follicular helper cells increases the affinity of the antibodies, making them more potent (71). 
The T follicular helper cells are also thought to drive inflammation by producing IL-4 (72). 
The secreted IgE is spread by the blood systemically, and further into tissues where it 
encounters mast cells, to which it binds using the high affinity receptor FcɛRI. The mast cells 
are now sensitized and ready to combat the allergen during subsequent exposure.  
 
Figure 1: Sensitization to allergens in the airway. Galli, S., Tsai, M. & Piliponsky, A. Nature 
454, 445–454 (2008). 
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1.2.4 Effector response 
The following time the allergen is encountered an allergic response initiates. The effector 
phase can be described as three stages, early, late and chronic phase. A few minutes after the 
allergen exposure, the early phase occurs when IgE-coated mast cells degranulate upon 
recognition of the allergen, cross-linking of FcεRI and releasing mediators causing 
inflammation, see figure 2. Symptoms occur such as asthma due to bronchoconstriction, 
swelling and redness because of vasodilation and rhinitis from mucus production (73).   
 
Figure 2: Early phase of allergen-induced airway inflammation. Galli, S., Tsai, M. & 
Piliponsky, A. Nature 454, 445–454 (2008). 
The late phase response occurs hours after the allergen exposure, and is a result of the innate 
and adaptive immune cells recruited by the chemokines, cytokines and mediators present at 
the site of inflammation. The innate cells cause damage to the epithelia, neutrophils release 
elastase causing collagen degradation (74) and eosinophils their major basic protein (MBP) 
destroying cells (75), see figure 3. 
If the inflammation is persistent, long-term damage to the airways through remodeling can 
occur. The smooth muscle cells in the lungs increase both in numbers and size, decreasing the 
lumen size, while mucus producing goblet cells become more abundant (76). With constant 
infiltration of immune cells, cytokines are further injuring the tissue (77). In non-allergic 
individuals, T regulatory cells contribute to keeping the balance of the immune system and 
produce IL-10 to inhibit activation of the TH2 pathway (78).  
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Figure 3: Late phase of allergen-induced airway inflammation. Galli, S., Tsai, M. & 
Piliponsky, A. Nature 454, 445–454 (2008). 
1.2.5 The mucosa in allergy 
The mucosal layers on the inside of the body are the surfaces that are directly exposed to 
pathogens and if breached, the normal entry point for microbes. These layers consist of a 
mucus secreting epithelium that covers the entire gastrointestinal tract, the respiratory tract, 
the urogenital tract and the middle ear, forming the largest part of the immune tissues (9). 
However, these tissues are permeable to allow substances such as nutrients or oxygen to pass, 
making defense an important feature. In an allergy context, when the body tries to fight off a 
perceived threat in the form of an allergen, the cells driving inflammation also causes damage 
in the bronchial tract. Lymphocytes in patients susceptible to allergic disease differentiate 
into TH2 cells, that together with innate lymphoid cells type 2 (ILC2) activate and start 
producing cytokines (79), figure 4. Secretion of IL-13 causes airway remodeling and airway 
obstruction, features of allergic asthma (80). Recruitment of eosinophils via the cytokine IL-5 
further drives inflammation and degranulation causing epithelial damage (81). Production of 
IL-4 induces naïve T cells to differentiate into TH2 cells creating a positive feedback loop and 
more recently has been shown to synergize with IL-3 to further enhance TH2 promotion (82). 
In addition, IL-4 has been shown to polarize macrophages into the alternatively activated M2 
macrophages through the inflammasome NLRP3 (83), potentially causing fibroblast 
accumulation and tissue remodeling through TGF-β secretion (84). 
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Figure 4. Overview of functions of TH2 cells and ILC2 cells in asthma. (Lambrecht B.N. & 
Hammad H., Nature Immunology 16, 45–56(2015)) 
The gut also plays a major role in the development of allergies, studies have shown that 
diversity of microbiota during infancy affects allergy and asthma outcome (85, 86). Further, 
impaired IgA ability to bind fecal bacteria predisposes children to develop allergies (87) and 
consuming breast milk with lower diversity of microbiota could facilitate this development 
(88). Richness of bacterial flora as well as composition in the saliva also impacts the 
probability to acquire allergic disease and discussions are ongoing regarding efficacy of 
probiotic prophylaxis (89). 
1.2.6 Mast cells and basophils 
Mast cells are found in all tissue vascularized in the body, but more abundantly close to 
epithelia, airways and the gastrointestinal tract. Diversely, basophils are encountered in 
circulation and only migrate into tissue during an immunological event (90). However, both 
cells express the high affinity receptor for IgE, FcεRI. When sensitized, allergen-specific IgE 
is bound to the receptor coating the cell. Upon allergen encounter, two or more IgE molecules 
bind the allergen, crosslinking the receptors leading to an aggregation of FcεRI (91). The 
aggregation activates a downstream process where the protein tyrosine kinases LYN and 
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FYN initiate a cascade resulting in degranulation, synthesis of pro-inflammatory lipid 
mediators and activation of transcription factors encoding cytokines, chemokines and growth 
factors (92). When degranulation occurs, histamine and lipid mediators, among others 
prostaglandins and leukotrienes, which cause vasodilation and swelling, are released. Further 
chemokines which induce migration of leukocytes to the site of inflammation, as well as 
TNF-α causing bronchoconstriction and pro-inflammatory cytokines such as IL-4, IL-5 and 
IL-13 are secreted (93). FcεRII or CD23 is the low affinity equivalent and can exist both 
membrane bound or soluble. It has the ability to inhibit IgE production when engaged on B 
cells (94) and when in soluble form has cytokine-like activity, promoting proliferation and 
sustaining cell growth (95). FcεRII is expressed on among others T and B cells (96), 
granulocytes (97) and monocytes (98). A new study has found a cross-talk between mast cells 
and basophils, where IL-33 produced by mast cells induce basophils to drive allergic 
inflammation (99). 
1.3 ALLERGENS 
1.3.1 Structure 
Allergens are generally small hydrophilic proteins or glycoproteins derived from the animal, 
plant or fungi kingdoms. Allergens contain conformational epitopes or in rare cases 
carbohydrate residues recognized by immunoglobulins (100). Galactose‐α‐1,3‐galactose (α‐
Gal), a carbohydrate residue with the capacity to induce IgE antibodies are associated to red 
meat allergy, but sensitization has been linked to tick bites (101). However, the mechanism is 
still not fully determined. Further, an allergen must have the ability to cross-link IgE on mast 
cell and basophil surfaces, which requires at least two IgE epitopes. Consequently, many 
allergens naturally exist as dimers or oligomers to facilitate the immune cell activation 
capacity (102).  
Another inherent ability of allergens is the stability of the protein, especially in regard to food 
allergens that have to withstand the gastrointestinal tract and proteases (103). The major 
peanut protein Ara h 1 and the hazelnut allergen Cor a 14 for instance, are able to survive 
digestion and to elicit severe allergic reactions (104, 105). The capacity to maintain 
conformation could also serve to slow down digestion by lysosomes after phagocytosis and 
contribute to a prolonged MHC class II presentation (106, 107). Lately, focus has been 
shifted to the adherent adjuvant properties of some allergens, such as their function as 
proteases and thus the ability to affect epithelial cells directly and drive TH2 inflammation 
(108).  
A large portion of the pet allergens belong to the lipocalin protein family (109), and the 
similarities within the group could explain the common pattern of multi-sensitization across 
species (110). The other three major protein families connected with pet sensitization are 
kallikrein, serum albumins and secretoglobin (111). Most animal allergens studied belong to 
pet mammals like cat and dog, or those in our proximity e.g. house dust mite. Less is known 
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about uncommon pets like reptiles or birds, however a toxin has been described for spiders 
(112).  
Allergen nomenclature is derived from the host species name. The Latin name of the Linnean 
system for dog is Canis familiaris and the allergens are thus named Can f and allocated a 
number in sequence, for instance Can f 1, Can f 2 and so forth. Equus caballus is Latin for 
domestic horse and the nomenclature for these allergens Equ c. The World Health 
Organization and the International Union of Immunological Societies Allergen Nomenclature 
Sub-Committee are responsible for recording and classifying characterized allergens (113).  
1.3.2 Sensitization to pets 
Sensitization to pet allergens increases the risk of developing allergy and asthma (114) and 
over 50% of studied children admitted to hospital for asthma exacerbations were shown to be 
sensitized to pet allergens, signifying the connection (115). The prevalence of allergy 
however differs between geographic locations and populations, where the westernized 
countries are more prone to disease development (116-118). Further, exposure to urban 
environments during childhood was connected with a higher risk of sensitization as an adult 
compared to rural settlement (119). During the last decades the sensitization rate in childhood 
to inhalant allergens has increased dramatically (120), although in older children in high 
prevalence areas, asthma development increase seems to come to a halt (121). Studies 
suggest a sensitization rate of 20% to dogs and 18% to cat in Sweden, but only 6% and 10% 
respectively in Palermo (116). In the US, a prevalence of 12% has been recorded for both 
dogs and cats (122). Sensitization to horse has been reported to 5% in one study in Italy (123) 
and 3% in another (124).  
1.3.3 Dog allergens 
Regarding dogs, eight allergens have been described to date, Can f 1-8 (Table I). Can f 1 is a 
major lipocalin allergen 23-25 kDa, found in dander and saliva (125). Approximately 70% of 
dog allergic individuals are sensitized to Can f 1 (126). Recently, a study revealed that the N 
and C-terminus of Can f 1 both contained a conformational IgE epitiope, possibly a target for 
future therapeutics (127). Can f 2 is a minor lipocalin, detectable in saliva, with an IgE 
reactivity of 23% and a size of 19 kDa (128). Can f 3, is serum albumin, abundant in blood, 
but can also be found in saliva and skin, possibly leaking through from damaged epithelia or 
gums. It is a larger protein, 69 kDa and cross-reactive with serum albumins from other 
mammals (129). Due to this, Can f 3 is less immunogenic with a prevalence of 35% 
sensitization (130). Can f 4, an 18 kD lipcocalin, was first thought to have a sensitization rate 
of 35% (131). It was in a later study displaying positive titers of up to 81%, suggesting the 
classification as a major allergen (132), possibly due conformational stability. Can f 4 also 
has the ability to form dimers, possibly affecting the allergenicity (133). Can f 5, prostatic 
kallikrein of 28 k Da, is also a major allergen with prevalence up to 76% among dog 
sensitized patients (134). Being a homologue to human prostate-specific antigen (PSA), it is 
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only expressed in male dogs, making avoidance easier (135). Case studies have also 
confirmed the link between Can f 5 sensitization and allergy to human seminal fluid (136, 
137). Another cross-reactive allergen of 27-29 kDa denoted Can f 6, has also been described 
in both fur and saliva with a sensitization of 38% (138). Can f 7 or Niemann Pick type C2 
protein, has been characterized as a 16 kDa protein with an IgE positivity of 10-20% (139). 
Recently, a novel allergen has been added to the IUIS Allergen database, a 14 kDa cystatin 
with a prevalence of 13% named Can f 8 (113). 
Mentions of hypoallergenic dogs have been frequent in media and popularity of cross-breeds 
with these claimed traits has risen. However, no scientific data supports the statement 
regarding hypoallergenic dog breeds. On the contrary, one study describes higher 
concentrations of Can f 1 in the acclaimed hypoallergenic breeds compared to other breeds 
(140). Others report no difference in allergen concentration between homes of so-called 
hypoallergenic dogs compared to control dogs (141). Further, a higher incidence of allergy in 
children growing up with these claimed hypoallergenic breeds was found. Conversely, a 
reduced risk of developing allergy was instead correlated with female dogs and keeping two 
dogs or more (142).  
Table I. List of currently known dog and horse allergens, their molecular weight, prevalence 
of sensitization and biochemical name. 
Dog allergens Size Prevalence Biochemical name 
Can f 1 23-25 kDa 70% Lipocalin 
Can f 2 19 kDa 23% Lipocalin 
Can f 3 69 kDa 35% Serum albumin 
Can f 4 18 kDa 35-81% Lipocalin 
Can f 5 28 kDa 76% Kallikrein 
Can f 6 27-29 kDa 38% Lipocalin 
Can f 7 16 kDa 10-20% NPC2 
Can f 8 14 kDa 13% Cystatin 
Horse allergens Size Prevalence Biochemical name 
Equ c 1 25 kDa 51-70% Lipocalin 
Equ c 2 17 kDa 50% Lipocalin 
Equ c 3 67 kDa 40% Serum albumin 
Equ c 4 17 kDa 77% Latherin 
Equ c 5 " " " 
Equ c 6 15 kDa Not reported Lysozyme 
1.3.4 Horse allergens 
Six horse allergens have been registered in the IUIS Allergen database (Table I).  Equ c 1, the 
major horse allergen, is a 25 kDa lipocalin protein (143, 144) with a reported IgE prevalence 
of 51-76% (145, 146). Equ c 2 has previously only been described as two incomplete 
isoforms of a 17 kDa lipocalin protein. IgE recognition in immunoblot was detected in about 
50% of patient samples, however no distinction was made between the different isoforms and 
only 23 patients were analyzed (147). Equ c 3 is serum albumin and holds a molecular weight 
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close to other albumins, 67 kDa (148). Sensitization rate reported is approximately 40% 
(149). Equ c 4, diversely is a latherin of 17k Da, with surfactant properties found in sweat and 
saliva (150). Equ c 5 was later described as an independent allergen, but found to be identical 
to Equ c 4 and removed from the IUIS database. Prevalence was only reported in the Equ c 5 
paper, 77% of 22 patients (151). Lastly Equ c 6, a lysozyme, was described in a case study 
and classified both as a contact allergen causing urticaria and a food allergen after ingestion 
(152). 
Similarly to dogs, hypoallergenic horses has been a hot topic. However, in concordance with 
the results for dogs, no evidence for the hypothesis has been found. Curly horses are 
classified as a hypoallergenic breed, but had significantly higher levels of horse dander 
antigens, Equ c 1 and Equ c 4, compared to several other breeds (153). Equ c 4 has a high 
variation both within and between ten different breeds, where only stallions had significant 
consistently higher concentration compared to mares and geldings (154). 
1.3.5 Cross-reactivity 
Due to pet allergens generally belonging to a select few protein families, cross-reactivity is 
common. Clinically, pet allergic patients often are multi-sensitized, making diagnosis more 
complicated, with mono-sensitization being as low as 5% (149). To elucidate the primary 
allergen source in poly-sensitized patients, molecular based allergy diagnostics is a useful 
tool (155). Two super-families of pet allergens are similar in structure and reported as cross-
reactive, lipocalins and serum albumin (156, 157). Lipocalin Can f 6, shares similar tertiary 
structure and sequence with the cat allergen Fel d 4 (158). Fel d 4 together with horse allergen 
Equ c1, also inhibit IgE binding to Can f 6 in vitro, implying cross-reactivity between the 
three allergens (138). However, in spite of a low sequence identity, Fel d 4 also displayed 
cross-reactivity with Can f 2 (159). Dog allergen Can f 4 also cross-reacts with an odorant 
binding cow allergen (131). Further, Fel d 7, a cat allergen that 46% of cat sensitized 
individuals react to, was shown to moderately correlate to Can f 1 and inhibit IgE-binding in 
dog sensitized patients (160). Three peptides from horse serum inhibit IgE and IgG from 
horse allergic patients to not only horse, but also dog and cat albumin (161). One third of 
patients sensitized to dog, cat and horse displayed cross-reactivity to all the serum albumins 
(162). Taken together, patients sensitized to above mentioned protein families should be 
further investigated, because the assumed primary sensitizing allergen might only be a cross-
reactivity, and another allergen actually the principal cause of allergic symptoms.  
1.3.6 Distribution 
Pet allergens are abundant in homes with resident pets, but can also be found in public places 
like schools and hospitals, making avoidance measures difficult for allergic individuals (163, 
164). A recent study even detected a higher concentration of allergen in day care centers 
compared to homes (165). Allergen reduction tools have proven some decrease of allergen 
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concentration and allergic symptoms, including air cleaners and recurrent washing of the 
animal (166-169), but avoidance if sensitized is recommended.  
The aerodynamic properties of allergens varies, where house dust mite allergens group I are 
carried mainly on particles averaging 20 µm (170). Cat and dog allergen associated particles 
however, belong to a broader range, where 20% of particles were smaller than 5µm (171). 
Smaller particles have the capacity to reach further down the airways, increasing the 
probability of uptake and encountering of mast cells, and sensitization to these have been 
correlated to inflammation and asthma (172). Comparison of allergens in settled dust in 
relation to the airborne compartment, showed correlation for homes with dogs, but not in cat 
households, suggesting these particles have further unknown properties (173). Airborne 
levels of horse allergen has been shown to disperse quickly, even in the vicinity of stables 
(174), where concentration was 500-fold lower just outside compared to inside the stable 
increasing to a 3000-fold difference 12 meters away (175). 
1.4 ALLERGY DIAGNOSTICS 
1.4.1 Skin prick test 
The golden standard of allergy diagnostics is still skin prick test (SPT) and the most common 
practiced (176). The method is usually performed using naturally derived aqueous extracts 
acquired from the allergen source (177). The standard procedure is conducted as described 
(178) by placing a grid on the patient’s forearm and adding a small drop of each allergen to 
be analyzed, as well as a negative (diluent) and a positive control (histamine solution). The 
skin is then pierced using a lancet. The grid is removed and excess solutions wiped off. After 
15 minutes the results is recorded by measuring the diameter of the wheal formed by the local 
immune reaction. A wheal diameter ≥3 is considered positive. The advantage of using the 
skin prick test is the cheap cost, it is quick to perform and well proven (179). To consider 
when using the skin prick test is that the positive control can influence the negative control if 
in close proximity (180). The physicians interpreting the result differently can also impact 
diagnosis (181). Further, because the nature of the extracts and lack of a consensus 
standardization (182), false negative responses can occur if an allergen is lacking from the 
analytic preparation or not present in adequate amounts to produce a reaction (183).   
1.4.2 Serology 
Detection of specific IgE antibodies in serum is another well-established method of 
diagnosing allergy (184). It was introduced in 1967 as a radioallergosorbent test (RAST) by 
Johansson and Wide (185). Several different methods are in practice today, where the single-
plex assays ImmunoCAP and Immulite 2000 are most commonly used (186, 187). The 
analyzed allergen can either be in an extract or a component, coupled to a solid phase. Sera is 
added and if allergen-specific IgE is present, it binds to the allergen. Detection is done by a 
fluorescent anti-human IgE, in proportion to the patient sIgE (188). The advantage of these 
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assays is that they quantify the sIgE in units per liter (kU/L), the sensitivity and precision is 
high, it is reproducible and IgG does not interfere with the measurement (189). The downside 
of the method is again the extracts and their content, or lack thereof. Especially in regard to 
food allergy where different molecules of the allergen source are connected with severity of 
symptoms (190). Lack of allergens in the extracts can, as in the skin prick test produce false 
negative results (191). Recently, multiplex analyses have been developed. These assays test 
for a large panel of common allergens simultaneously and use lesser sera per allergen tested 
(192). Another advantage is that they are often component resolved, which improves the 
accuracy (193). Further, in multi-sensitized individuals, deducing cross-reactivities and 
detecting the primary sensitization profile is less complicated (194). 
1.4.3 Extracts and components 
As mentioned, the extract based assays struggle with sensitivity, due to the varying 
composition of extracts (195). Preparation of the raw material into aqueous extracts also 
causes inconsistencies. Some methods destroy conformational epitopes and, additionally, 
selection of the raw material can impact the composition of allergens (177). Even different 
batches from the same manufacturer differ in patient SPT responses (196). The varying 
protein content and composition of SPT solutions have been demonstrated for dog dander and 
the possible impact on the accuracy of diagnosing allergy to dogs (197). Further, due to the 
allergen variability of dogs and lack of low molecular weight allergens in extracts, 
inconsistencies cause difficulties in diagnosis (198). The same phenomenon has been shown 
for fish extracts, where different manufacturers varied 10-fold in content, (199) and in 
extracts for cockroach allergy diagnostics (200). Molecular components provides a solution 
to the inconsistencies of extracts, by having a consistent allergen content, thus making 
standardization possible (201). Further, the issue with unknown molecules and their 
properties are non-existent. In cockroach extracts for example, glycinin is not unlikely 
present, due to contamination from their food source. Patients sensitized to soybean can 
respond positively although they are negative for cockroach, providing a false diagnosis 
(202).   
1.5 TREATMENT OF ALLERGY 
1.5.1 Allergen specific immunotherapy 
The only curative treatment currently available for allergies is allergen specific 
immunotherapy (AIT), where desensitization is achieved by administrating the relevant 
allergen in low doses over a long period of time gradually increasing the dose (203). 
However, no standardized protocol exist, physicians worldwide practices different doses and 
frequency of treatment, complicating understanding of efficacy (204). As with the skin prick 
test, AIT relies on allergen extracts. Due to the absence of a common standardization and 
wide range of administered doses, knowledge on effective doses are lacking (205). The 
mechanism of AIT encompasses shifting the TH2 immune response into a TH1 pathway 
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including blocking IgG antibodies and induction of IL-10 secreting T regulatory cells (206). 
IgG1 and IgG4 in response to AIT, can compete with IgE-allergen complexes for binding the 
low affinity FcγRIIb on B cells, thus inhibit the antigen presentation to T cells promoting 
tolerance (207). 
Two methods are in practice in the clinics today, subcutaneous immunotherapy (SCIT) and 
sublingual immunotherapy (SLIT). SLIT is less invasive, where tablets are orally 
administered compared to SCIT, where the allergen is injected under the skin, but suggested 
as less effective (208). However, from a safety perspective SLIT is advantageous, less 
adverse systemic reactions are reported but local responses are more frequent. Although 
uncommon, SCIT can cause potentially lethal anaphylaxis, which should be taken into 
account when initiating treatment (209). Studies on treatment of allergy to pets display 
divergent results. For dog AIT, a review of clinical trials show inadequate results after 
therapy attributed to inferior extracts and the numerous dog allergens in relation to patients’ 
divergent sensitization profiles (210). A case study report states that AIT to dog can decrease 
allergic responses to other furry animals, likely due to cross-reactivity (211). Not many 
studies have been conducted on AIT on horse allergic patients, but one study found that 
rhinitis lessened for 93% of the patients and asthma symptoms reduced for 90% (212). 
1.5.2 Immunomodulation 
A large concern regarding immunotherapy is safety, anaphylaxis and severe systemic 
reactions poses danger to patients undergoing treatment (213). To combat the issue, as well as 
increasing the efficacy of the treatment, different strategies has been applied to modify the 
therapeutic allergens. For example, allergoids are chemically modified allergens, by 
polymerization with aldehydes conformational IgE-epitopes can be destroyed while 
sequential T cell epitopes are retained, thereby reducing allergenicity while maintaining 
immunogenicity (214). A cat dander allergoid induced a TH1 and T regulatory response in 
vitro and lesser IgE interaction (215). Further, a HDE allergoid has proven well-tolerated in 
several clinical trials (216). Another strategy involves DNA containing unmethylated CpG 
oligodeoxynucleotide (ODN), a feature of bacterial and viral genomes. It is recognized by 
toll-like receptor 9, which has the capability of switching a TH2 response into a TH1 milieu 
(217). CpG ODN has been utilized as an adjuvant in treatment of peanut allergy (218, 219). 
Traditionally, adjuvants has been added to vaccines for boosting the efficacy, where 
aluminum hydroxide has been frequent choice. However, the mechanisms are still not fully 
understood, but several advances have been made (220). 
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2 THESIS AIM 
The aim of this thesis is to increase the understanding of the molecular aspects of pet 
allergens, specifically those belonging to dog and horse, and their implication in diagnosis 
of allergy to pets. By identifying causative allergens, characterize their properties and 
distribution and thoroughly examine allergen profiles and patient sensitization patterns the 
goal is to improve molecular diagnostic methods and subsequent treatment. 
Specific aims: 
Paper I: To compare two microarray multiplex assays to conventional diagnostic methods, 
skin-prick test and singleplex serology, in terms of specificity and sensitivity. 
Paper II: To analyze commercial skin prick test extract used for diagnosing allergy, 
determining their content and levels of allergen components. Further, to examine allergen 
profiles of a dog population.  
Paper III: To determine IgE profiles in horse sensitized patients and to characterize novel 
and previously poorly described horse allergens. 
Paper IV: To detect dog allergens in the air utilizing different sampling methods and to 
elucidate the aerodynamic properties of individual allergens.  
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3 MATERIAL AND METHODS 
Below follows a recount of the patient material analyzed in the papers and a description of 
the major methods experimentally applied. Further details are accessible in the material and 
methods section of each respective paper. 
3.1 MATERIAL 
3.1.1 Patient material 
In paper I, children (n=71) were recruited from a nationwide study of severe asthma. The 
children underwent an extensive doctor’s examination and were well characterized before 
receiving the diagnosis severe problematic asthma (221). Written informed consent was 
obtained from all participants. Sera from dog allergic patients were obtained from voluntary 
donors for paper II, written informed consent was given and the material stored in our 
biobank in accordance with GDPR. Horse allergic patient sera (n=180) were provided by 
Clinical immunology at Karolinska University Hospital, Stockholm, Sweden and control sera 
(n=25) from Thermo Fisher, Uppsala, Sweden for paper III. All studies were approved by 
the regional board of ethics.  
3.1.2 Animal material 
In paper IV, four dogs and their owners were recruited. No ethical approval was obtained, as 
it is not needed for privately owned pets according to Swedish Board of Agriculture statutes, 
provided that certain conditions are fulfilled during the experiment. Thus the set requirements 
were met, i.e. owners informed consent, the animal reside in its normal environment (not 
separated from the owner), no invasive actions, no fixed positioning of the animal, no activity 
causing suffering or distress. Polyclonal rabbit antibodies were purchased from Agrisera AB, 
which hold a permission from Umeå animal ethics board for antibody production. BALB/c 
mice were immunized with recombinant allergens to produce polyclonal anti-Can f 4 and 
anti-Can f 6 for papers II and IV. The immunizations were approved by the Stockholm 
animal ethics board. 
3.2 METHODS 
Aerosol particle collection 
(Paper IV) 
Particle collection both by PTFE filters at 
flowrate 20 L/min or 40 L/min operated by 
an air pump and liquid cyclone sampling into 
PBS at flowrate 200 L/min. 
Airborne particle detection 
(Paper IV) 
Sampling of air at 60 L/min using a cascade 
impactor with eight size fractions range 
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<0.34->8.13 µm. 
Antibody production 
(Paper II & IV) 
Immunization of BALB/c mice or rabbits 
with recombinant allergens subcutaneously to 
induce an allergen specific immune response. 
Basophil activation test (BAT) 
(Paper III) 
Determination of basophil degranulation 
upon stimulation of whole blood with 
allergens by flow cytometry after staining for 
the basophil marker CD203c and the 
degranulation marker CD63. 
Inhibition ELISA 
(Paper II & IV) 
Allergen measurement by ELISA, where 
sample competes with biotinylated 
recombinant allergen for allergen specific 
antibody binding. Detection with secondary 
enzyme labelled antibody. 
ImmunoCAP 
(Paper I & III) 
Quantification of allergen-specific serum IgE 
by singleplex assay. The test vial contains a 
solid cellulose phase coupled with allergen 
extracts or components. Detection by 
secondary fluorescent antibody. 
ImmunoCAP ISAC 
(Paper I) 
Quantification of allergen-specific serum IgE 
by multiplex assay with biochip technology. 
112 allergen components are immobilized in 
a microarray. Staining with secondary 
antibody after serum incubation.  
Microtest allergy system  
(Paper I) 
Quantification of allergen-specific serum IgE 
by a multiplex assay with 35 allergen extracts 
and components from 22 sources 
immobilized on a glass slide. Detection by 
secondary fluorescent antibody. 
Protein identification 
(Paper III) 
Candidate allergens were identified by 
immunoblot. Corresponding protein bands 
excised and digested by trypsin. Peptides 
were discerned by tandem mass spectrometry 
and pBLAST search for full length sequence. 
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Protein quantification 
(Paper II) 
Protein concentration determination by 
bicinchoninic acid assay, BCA. Detection by 
colorimetric measurement. 
Purification of antibodies 
(Paper II & IV) 
Immunized sera from mice or rabbits are 
purified by affinity chromatography using the 
allergen of interest as the immobilized ligand.  
Production of allergens from natural source 
(Paper II, III & IV) 
Purification of allergens from natural source, 
animal dander or urine, by size exclusion 
chromatography (SEC) and ion exchange 
chromatography (IEC). 
Production of recombinant allergens 
(Paper II, III & IV) 
Synthetic genes of interest are cloned into 
expression vectors for protein expression in 
E. coli or HEK293 cells (Can f 5, Paper II). 
The expressed recombinant proteins, 
containing histidine tags, are purified by 
immobilized metal chelate affinity 
chromatography (IMAC), size exclusion 
chromatography (SEC) and ion exchange 
(IEC) chromatography. 
Quantitative ELISA 
(Paper II & III) 
Allergen specific serum IgE is quantified 
using recombinant or natural allergens. 
Detection with secondary enzyme labelled 
antibody. 
Skin prick test (SPT) 
(Paper I & II) 
Skin allergen challenge with naturally 
derived extracts. Sensitization is measured by 
diameter of wheal in response to challenge 
and compared to positive and negative 
controls. 
Protein analysis 
(Paper II) 
Size and purity analyzed by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). Separation of proteins 
according to size under reducing conditions. 
Statistical methods Paper I: Spearman rank correlation 
coefficient was used for the concordance of 
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(Paper I-IV) 
methods. Sensitivity, specificity and the 
positive and negative predictive values were 
calculated as well as the positive and 
negative likelihood ratios. Paper II: To 
compare gender, Mann‐Whitney U test was 
used, to compare breeds, 
Sidak's multiple comparisons, and to 
compare Can f 4 to the other allergens 
Dunnett's multiple comparisons test was 
utilized. Paper III: Linear regression was 
used to assess correlation between the two 
Equ c 2 forms. Paper IV: No statistics applied 
due to it being a pilot study with only four 
participants. 
3.3 ETHICAL STATEMENT 
All experiments on human and animal material were approved by the regional ethics 
committee and conducted in accordance with Swedish regulation and animal welfare laws. 
Written consent was obtained from all blood donors providing sera for serology and basophil 
activation test. For the human material, no major invasive procedures occurred, only a small 
puncture wound for venous blood sampling. The children in paper I were further subjected to 
skin prick test, which has no severe patient risks, only local irritation and swelling. In regard 
to this, safety issues is not a major cause for concern. However, the collection of patient data 
and storage of personal information needs to be taken into consideration. This could 
jeopardize patient integrity if misplaced and should be handled with care. We keep all our 
records coded on a secure server in accordance with general data protection regulation 
(GDPR). In regard to this, all serum samples, marked with their study code, are stored in our 
biobank in accordance with the Swedish biobank act. Patients give their consent to store 
samples in a biobank, are informed that their samples will only be used for the purpose they 
consent to and that they have the right to request at any time to have their stored samples 
destroyed.  
The animal experiments imply the use of other species without their consent and for human 
benefit, which is a general ethical dilemma. The immunizations are minimally invasive and 
likely the handling causes more stress than the injection. Drawing of blood causes slightly 
more distress and tends to render the animals exhausted. At end point the animals are 
euthanized, which again raises ethical concerns. To minimize damage and suffering when 
using animal experiments, we implement the three Rs, reduce, replace and refine. Further, all 
personnel handling the animals have the appropriate education where ethics and animal 
welfare are central.  
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4 RESULTS AND DISCUSSION 
4.1 ALLERGY TESTING IN CHILDREN WITH PERSISTENT ASTHMA: 
COMPARISON OF FOUR DIAGNOSTIC METHODS [I] 
Routine diagnostics of suspected allergy is conducted by skin prick test and/or serology (222, 
223). However, these methods mostly rely on naturally derived extracts with poor 
characterization of composition for analysis (224). Multi-sensitization is common for pet 
allergic patients, where determining the primary sensitization source can be challenging 
(225). To add complexity, many of those sensitized are children or adolescents (226, 227).  
Further, to understand cross-reactive patterns and predictions of severity of allergic reactions, 
knowledge of component sensitization is essential (228). Multiplex assays containing an 
array of allergen molecules could provide more detailed information and improve the 
accuracy of diagnosis (229). In this paper we compared two multiplex assays, ImmunoCAP 
ISAC 112 and the Microtest allergy system, to the conventional methods skin prick test and 
the singleplex ImmunoCAP, and with doctor’s diagnosis on children with persistent asthma 
from a defined cohort (221). To account for the two standard methods limit in number on 
analyses practicable, ten allergens were selected for comparison, despite the actual number 
tested by the multiplex assays. Of seventy-one participating children, 27% were sensitized to 
1-2 of the 10 selected allergens and 48% were multi-sensitized to 3-8 of the identical 
allergens, see figure 5. This indicates that allergies are a common affliction in persistent 
asthma and children with the condition should be investigated for sensitization. 
 
Figure 5. Prevalence of allergy/IgE sensitization according to doctor’s diagnosis, Microtest, 
ISAC, ImmunoCAP and SPT. 
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Analyzing the results for concordance of methods, comparing them two and two yielding 
3964 pairs, gave 90-92% concomitance regardless of method. However, at low sensitization 
levels all chosen allergens and irrespective of method showed divergence, possibly due to the 
allergen extracts or technological limitations of the assays. The issues with extracts were 
further demonstrated by a negative SPT to birch in 18 highly sensitized patients according to 
all three in vitro methods and doctor’s diagnosis. This was later explained by the 
manufacturer as a faulty batch, but highlights the problems with naturally derived extracts.  
 
Figure 6. Quantitative comparison with ImmunoCAP IgE concentrations on the x-axis vs 
ISAC and Microtest sIgE concentrations on the y-axis for different allergen sources and the 
Spearman correlation coefficient (r). Each patient’s results are represented by two dots: filled 
diamond represent ImmunoCAP vs Microtest and unfilled squares represent ImmunoCAP vs 
ISAC. 
Further, the accuracy of the methods was compared by evaluating the ability to detect specific 
IgE towards an allergen extract. Of 710 results, 593 observations were in negative or positive 
agreement across all four methods. No significance in accuracy was discovered between the 
two microarray methods compared to the standard procedures, see figure 6. Interestingly, 
detection of dog sensitization on ISAC failed to recognize 13 of 28 patients with positive IgE 
on ImmunoCAP and doctor’s diagnosis. This could be due to ISAC lacking several dog 
allergen components and the patients being sensitized to those, underscore the importance of 
identification of new allergens and the importance of a full panel of allergens in diagnostics. 
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The same 710 results were moreover compared with doctor’s diagnosis, where the positive 
divergent outcomes ranged from six to fifteen, where SPT had the fewest discrepancies and 
ImmunoCAP the most. The negative inconsistent observations were more abundant, from 21 
(ImmunoCAP) to 41 (SPT). Overall, sensitivity was calculated to 0.77–0.88, and the 
specificity to 0.97–0.99 of the four methods compared to doctor’s diagnosis. Interestingly, 
both standard methods had the most dissonant results.  
To assess the added value of multiplex assays and the increased information received, 
allergen components were analyzed. Six children were sensitized to Ara h 8, a peanut 
allergen which exhibit cross-reactivity with birch (230). Distinguishing sensitization to Ara h 
8 and Ara h 2, another peanut allergen is also of great importance, as Ara h 2 is associated to 
systemic reactions (231). Multi-sensitization to animal lipocalins of several species were also 
found in eight patients. Seven children were also found to have positive IgE to molds and 
mites, this is uncommon in Sweden, and could forego detection during conventional 
diagnosis. However, the information regarding sensitization is valuable to minimize 
exposure. Comparison of sensitization profiles made possible to distinguish species specific 
IgE reactivity from cross-reactivities in nine children. In total, 47% of the patients received 
additional specific IgE information when analyzing components. Microarray analysis are 
more costly, but in multi-sensitized patients they offer added value, high-resolution and likely 
a more accurate diagnosis. Further, in children the benefit of lesser sera used per analysis is 
also advantageous.  
4.2 ALLERGENS IN DOG EXTRACTS: IMPLICATION FOR DIAGNOSIS AND 
TREATMENT [II] 
Allergy to dogs is a common disease, where 5-10% of the population is affected and 
regionally up to 20% (120). Skin prick test is one of the common methods of diagnosing 
allergy. The test is performed using aqueous extracts produced from the natural allergen 
source (232). Unfortunately, there is a lack of standardization of extracts and content is 
poorly defined (179). Further, the source differs between manufacturers, where hair, epithelia 
and dander are used. Eight dog allergens have been described to this day, Can f 1-8 (113). In 
this paper we have cloned and produced or purified six of these allergens to characterize five 
commercial skin prick test extracts. The results display a large variety of both concentration 
and composition. The total protein content differed from 1.53 to 3.07 mg/mL, where the 
defined allergen content detected only reached a fraction of the protein amount. As little as 
0.26% from one manufacturer up to 10% as the maximum portion. This raises the question of 
what the rest of the content consists of. It has been shown that some manufacturers add 
albumin as a buffer solution, however albumin of different species is cross-reactive which 
could affect the results of the skin prick test (197). Due to the largely uncharacterized protein 
content, positive reactivity could be towards other potential allergens. It could also be 
partially dissolved proteins, different extraction methods can affect the protein structure and 
could denature some proteins independently of others. Resulting in rendering conformational 
epitopes nonfunctional for some allergens, while possibly leaving others intact. 
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The six allergens analyzed were detected in all of the extracts, however the amount differed 
considerably. Can f 3 showed the most diversity in proportions, from 19% to 98% of the total 
allergen content, see figure 7. We also tested the extracts for human serum albumin, but 
found only low levels, not enough to explain the large proportion of albumin. Possibly it 
could belong to another species, which could recognize our Can f 3 antibody, due to the 
homology of serum albumins. Can f 1, the major allergen was only found in minute 
concentrations (15ng/mL) in one of the extracts, compared to the others ranging 1200-9100 
ng/mL. This could have implications for diagnosis, when 70% of dog allergic patients are 
sensitized to Can f 1. Overall, Can f 2 and Can f 6 were also detected at low concentrations. It 
is questionable if the amounts are clinically significant and there is risk of false negative 
diagnosis when applying these extracts. Can f 6, with a proportion of down to 100 fold lower 
than Can f 1, still is a consequential allergen due to the cross-reactivity to cat and horse 
allergens. Even between batches the relation between allergens differed, albeit not to the 
extent as between manufacturers. A problem is that the manufacturers have not means of 
analyzing allergen components. The only assay available commercially is for detecting Can f 
1, which some companies refer to as calibration. However, since the extracts are composed 
from naturally derived sources, these can differ not only in concentration but in proportion 
between allergens.  
 
Figure 7. Distribution of six dog allergens, Can f 1‐6, in ready‐to‐use SPT solutions (1‐5) 
from five suppliers (A), two batches (a and b) of skin prick test (SPT) solutions from two 
manufacturers (B) and in allergen source material extracts (6‐8) from one vendor and (9) 
from another supplier (C). 
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Lastly, raw material from three different sources, epithelia, hair and dander, was analyzed and 
found to heterogeneous. Epithelia and dander contained mostly Can f 3, while in hair, Can f 1 
was more dominant. Highlighting the importance of carefully selecting source material when 
manufacturing extracts. Choosing a more diverse source will likely produce a more balanced 
and well comprised extract. An alternative could be to mix material, including additional 
sources such as saliva or urine, that could contain site specific allergens. 
The lack of sensitivity was also demonstrated in a basophil activation test, specifically the 
CD-sens method was applied. Three dog allergic patients with different sensitization profiles 
donated blood for testing the extracts capability of inducing an allergic response. One of the 
patients was monosensitized to Can f 6 and only reacted to two of the extracts. The second 
patient with low IgE towards three of the dog allergen components, only responded to the 
highest concentration of two of the extracts, not sufficient to produce a CD-sens value. The 
last patient, sensitized to a large extent towards all allergens displayed positivity to all 
extracts except one, where again only the highest concentration was able to evoke reactivity. 
The extract used in Sweden’s routine allergy diagnostics would fail to detect the allergic 
response from two of these patients, hence those might not receive a correct diagnosis. 
 
Figure 8. Concentration (ng/mL, y‐axis) of six allergens (x‐axis) analyzed in extracts of fur 
sampled from the neck (A) and of saliva (B) collected from 120 dogs. Mean with standard 
deviation shown. Can f 2 is not detectable in fur. Saliva concentration is approximately 100‐
fold higher compared to fur. 
Lastly, to increase understanding of the nature of the extracts, a dog population (n=120) was 
tested for levels of allergen components in fur and saliva, see figure 8. In general, higher 
concentrations of allergen were accounted for in saliva, which could cause difficulty for 
allergic people despite the dog being washed regularly. The most abundant allergen in both 
fur and saliva was Can f 4. A recent study has implicated Can f 4 as a major allergen, with 
sensitization rates up to 81% (132). Thus, it is possible to have as great an impact on dog 
allergic patients as Can f 1, where most studies on sensitization and prevalence have focused. 
Moreover, the dominance of Can f 4 on dogs did not reflect the composition of the extracts. 
Sensitization can thus be underestimated, due to the extracts’ imbalanced content. Can f 2 
was only detected in saliva, not in fur. The extracts are made from hair and dander, where 
Can f 2 was detected only in low amounts accordingly. This again could have implications 
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for monosensitized individuals whom could remain undetected and wrongly diagnosed. The 
same but opposite was true for Can f 5, the PSA homologue found only in fur, likely due to 
contamination from urine. Can f 5 was further also detected only in intact male dogs, which 
was expected, none the less not proven previously. Trace amounts were found in fur samples 
from a few female dogs, this could be due to contamination from the household having 
several dogs. Not only did the variation of allergen profiles vary greatly in the population, 
individuals from the same breed exhibited as large diversity within the breed as inter breeds. 
Thus, the idea of hypoallergenic dogs are false, in concordance with previously published 
results (140). 
4.3 IGE PROFILING OF HORSE SENSITIZED SUBJECTS USING A PANEL OF 
HORSE ALLERGENS, INCLUDING THE NOVEL ALLERGEN EQU C 7 AND 
FULL LENGTH EQU C 2 [III] 
Allergy to horse is dependent on sensitization to horse allergen components, where 
knowledge is incomplete and still to be described allergens likely to contribute (145). 
Unfortunately, not many studies on horse allergy and treatment have been conducted, despite 
horses being utilized by mankind for thousands of years (233). Currently, five horse 
allergens, one duplicate, have been described, denoted Equ c 1-6 (113). In this article, we 
aimed to establish the sensitization rates to allergen components in a horse sensitized patient 
cohort. For this purpose, we produced recombinant Equ c 1, the major horse allergen, as a 
reference allergen. Sixty-one percent displayed positive IgE binding to the allergen, in range 
of previously reported 51-76% (145, 146). 
Moreover, we produced two forms of Equ c 2, previously only partially characterized (147). 
Using pBLAST search, a protein originating from Przewalski’s horse, a feral descendant of 
domesticated horse (234) aligned with the Equ c 2 N-terminal sequence. Further search using 
Przwalski’s Equ c 2 as template yielded a homologue from modern horse. The two Equ c 2 
forms displayed a 67.1% sequence identity and 90.6% similarity, rendering speculation 
regarding the two forms being isoforms justified, due to the relatively low identity. However, 
analyzing patient sensitization patterns, the forms correlate strongly and the vast majority 
sensitized to Equ c 2 responded to both forms. Interestingly, Przewalski’s Equ c 2 induced 
higher IgE titers, compared to the modern horse form, indicating more allergenic properties 
see figure 9. Many isoforms of allergens have different capability of inducing an allergic 
response, and even hypoallergenic isoforms exist (235, 236). Further, sensitization to the two 
Equ c 2 forms was quantified to 15 and 16% of horse sensitized patients, compared to the 
previously reported incidence of 50% (147). Nevertheless, that prevalence was deduced using 
immunoblot applying not fully characterized allergen extracts, possibly including several 
isoforms. A possible additive effect from the allergenicity of different isoforms could 
contribute to a higher reactivity observed. Another implication of Equ c 2 sensitization is due 
to it being a lipocalin, because the protein family often cross-reacts with other members and 
determining the primary sensitization allergen can prove cumbersome (237).  
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Figure 9. Quantitative analysis of IgE to two forms of Equ c 2 by ELISA. 
A. IgE titers (kU/L) to modern horse Equ c 2 among 80 HDE positive sera. B. IgE titers 
(kU/L) to Przewalski’s Equ c 2 among 80 HDE positive sera. Included also IgE-values of 25 
negative control sera to each component. The dotted line indicates positive cut off (0.35 
kU/L). Bars indicate mean value of the full population and one SD. C. Correlation between 
the two Equ c 2 variants. 
Additionally, we discovered a novel horse allergen, Equ c 7, by analyzing SDS-PAGE and 
immunoblot of horse dander extract. Sequence alignment identified a homologue in cat, the 
major allergen Fel d 1, to which 90% of cat allergic patients respond to (238). Protein 
sequence identity was confirmed to 55.7% with 82.0% similarity. The IgE reactivity was also 
confirmed with 38% of horse allergic patients responding to the allergen, see figure 10. Due 
to the similarities, cross-reactivity is likely to manifest and some of these patient might be 
primarily sensitized to Fel d 1. Further investigation of the allergen and its cross-reactive 
nature is warranted.  
 
Figure 10. Quantitative analysis of IgE to the novel allergen Equ c 7 by ELISA  
IgE titers (kU/L) to Equ c 7 among 80 HDE positive sera. Included also 25 control sera to 
each component. The dotted line indicates positive cut off (0.35 kU/L). Bars indicate mean 
value of the full population and one SD.  
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Lastly, to increase the understanding of the allergenicity of Equ c 4, latherin was purified 
from horse dander extract. Previous sensitization has been reported to 77%, indicating the 
importance as a major allergen. However, the study was performed on what was then though 
to be a novel allergen and not regarded as Equ c 4, further, only 22 horse sensitized patients 
were analyzed in the same study (151). Latherin is a surfactant protein and present in horse 
sweat, thus hard to avoid in proximity to horses.  Moreover, stallions have a higher secretion 
of Equ c 4 compared to mares and geldings, which could contribute to the severity of allergic 
response (154). Examining IgE response of 100 consecutive horse sensitized patients 
revealed a prevalence of 59%, still significant as a major allergen and should be taken into 
consideration when diagnosing allergic individuals. The panel of horse allergens are still not 
fully characterized and likely undescribed allergens contribute to sensitization. As we have 
shown in dogs, certain allergens are restricted to specific anatomical sites of the animal. 
Horse AIT are not conducted in Sweden currently, due to low efficacy. This could be a result 
of allergen not present in the extracts. Further, a large heterogeneity exist in commercially 
available extracts, as shown for dogs and fish (197, 199). Indeed, it is a common feature 
among allergen extracts to exhibit a large variety in content. Action is urgent to characterize 
allergens and producing them recombinantly, spiking extracts with these could improve 
diagnostics drastically and possibly therapy.  
4.4 AIRBORNE ALLERGENS FROM DOGS - QUANTITATION AND PARTICLE 
SIZE [IV] 
Exposure to animal allergens occur in our everyday life and the molecules they shed disperse 
and deposit in most public places (239, 240). Knowledge about allergen structure, secretion, 
aerodynamic properties and dispersion pattern are crucial to prevent unnecessary subjection if 
allergic. Data collected from earlier studies have only focused on Can f 1, showing that the 
allergen when airborne, is connected with mostly larger particles (> 9µm) but can also be 
found on particles as small as < 4.7µm (171). Smaller particles reaches further down the 
airways when inhaled, thus have the ability to deposit in the alveoli and have been associated 
with inflammation and asthma (241). To investigate the properties of airborne dog allergens 
Can f 1, Can f 3 and Can f 4, we utilized a 27m3 steel chamber with controlled air flow rate. 
The advantage of the chamber is the enclosed environment and reduction of contamination 
found in other studies partaking in people’s homes. Four dogs spent 2 hours each inside with 
their owner keeping the dog active. Fur and saliva samples were also collected for 
comparison with airborne particles. The saliva had generally higher allergen levels, for Can f 
1 24000-2200 ng/mL and >1600-256 ng/mL for Can f 4. In fur the range was 9.2-95 ng/mL 
for Can f 1 and <2.5-3.6 ng/mL for Can f 4. Can f 3 was not detected in any fur sample and 
only in saliva from dog #4. Can f 3 being serum albumin, therefore it might not be found in 
fur unless the dog has a wound or fractured skin where blood can leak out. The inability to 
detect Can f 3 in the samples is thus not surprising. The absence of Can f 3 in the dogs’ fur 
mirrored the airborne results, where Can f 3 was not detected regardless of method. 
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Figure 11. Amount of dog allergen detected in fractionated airborne particles. Particle size in 
fractions as follows from left to right <0.34 μm, 0.34 – 0.56 μm, 0.56 – 0.95 μm, 0.95 – 1.67 
μm, 1.67 – 2.85 μm, 2.85 – 4.51 μm, 4.51 – 8.13 μm and >8.13 μm. Can f 1 was found in the 
three largest size fractions, no detection in the other fractions. Can f 4 was detected in all 
fractions. 
To detect and separate particles of different sizes a cascade impactor with eight compartments 
was used. For all four dogs, Can f 1 was only detected in the three largest fractions, belonging 
to particles with sizes over 2.85 µm. Diversely, Can f 4 was found in all fractions, connecting 
the allergen with particles of many different sizes, see figure 11. The capability to attach to 
smaller particles could also influence the allergenicity of Can f 4, where lesser particles can 
reach the small airways and thus increase the likelihood to encounter mast cells and 
macrophages to initiate an allergic response (242). Allergens connected with particles less 
than 5 µm, have in sensitized patients been associated with asthma and inflammation (172). 
As recent studies has implicated Can f 4 as a major allergen with a sensitization rate up to 
81% (132), the impact of Can 4 exposure can contribute to eliciting allergic responses to 
large degree. Of note, as shown in Paper II, Can f 4 is the most abundant allergen in dog fur, 
further underlining its importance. However, in the dogs examined in the present study Can f 
1 was more abundant than Can f 4. This apparently contradictory result can be explained by 
the high individual variation in allergen levels between dogs.    
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Figure 12. Allergens collected by air pump and air cyclone. A. Amount allergen per m3 
collected from air filters (average of 20 lph and 40 lph) from each dog (1-4). B. Amount 
allergen per m3 in the liquid cyclone samples, 10 minutes collection per sample, average of 
two samples per dog (2x10 minutes). Low levels (<1.8-3.6ng/ml) of Can f 4 was detected 
from dog #1-3. 
The chamber had two PTFE filters, with an air flow rate of 20/40 liters per hours installed. 
Can f 1 and Can f 4 was detected in all air filters, however in samples from dog #1-3 Can f 1 
was the dominant allergen, while higher levels of Can f 4 compared to Can f 1 were detected 
from dog #4, see figure 12. Samples were also collected using a liquid air cyclone, 2x10 
minutes per dog. Interestingly, the results were opposite to those observed from PTFE filters. 
In samples from dog #1-3, only Can f 4 could be detected and from dog #4 Can f 1 was 
exclusive. The overall higher proportion of Can f 4 in the cyclone samples could be a 
consequence of different aerodynamic properties. As shown with the cascade impactor, Can f 
4 was connected with particles of all sizes, not only larger ones. This could enable them to 
prolonged time airborne or reach further distances. Also, the collection time between the 
filters and the cyclone differed, 2 hours compared to 2x10 minutes, which could account for 
the discrepancy of composition. Further studies are needed to investigate the properties of 
airborne particles and to find out how collection method impacts the recovery of allergens 
and implications thereof.  
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5 CONCLUSIONS 
Paper I: We compared two microarray assays to standard diagnostic methods, skin prick test 
and ImmunoCAP with doctor’s diagnosis. Concordance of accuracy was similar regardless of 
method, suggesting no diagnostic drawbacks of microarrays. The advantage of Microtest is to 
provide both extracts and components, decreasing the likelihood of missing a relevant 
component not present on the chip. ISAC however, is vastly superior in component diversity 
with 112 allergens, but could fall short in rare sensitization profiles. The downside of 
microarrays is the cost compared to the conventional methods and in monosensitized patients 
they provide no extra benefit. The additional specific IgE information achieved in half the 
sensitized children from microarray analysis provides physicians with improved tools aiding 
diagnosis. In multi-sensitized individuals this could be valuable, distinguishing primary 
sensitization from cross-reactivities. Certain allergen components are more clinically relevant 
and thus important to identify. As we show in paper IV, allergens have different aerodynamic 
properties and some are localized on different parts of the animal. Understanding of the 
sensitizing component’s characteristics could help in managing the allergen, for example 
avoiding male dogs or saliva.    
Paper II: The study analyzed commercially available skin prick test extracts for allergen 
concentration and composition. The results showed a large variation of content, where some 
allergens were only present in minute concentrations. The allergens present at very low 
concentrations may appear as not clinically relevant. The physician to diagnose the patient 
will have a difficult dilemma, where the test is negative but the patient’s anamnesis say 
differently. There is further a large portion of uncharacterized dog proteins, proteins, which 
may be allergenic or non-allergenic, but possibly also from other sources than dog. Because 
the extract is naturally derived, there is a possibility of cross-contamination with for example 
pollen or fungi. This could result in an opposite dilemma, rendering a false positive response. 
In our study, the dominating allergen found in the extracts differed to that of a population of 
dogs. This could be due to extraction methods favoring certain allergens while dissolving 
others, the implication is, nonetheless, that the extracts are capable of only detecting 
sensitization to select allergens. Utilizing poorly defined extracts for diagnosis could 
jeopardize patient safety, as insufficient amounts of certain allergens of clinical relevance and 
inconsistencies between batches could result in an incorrect diagnosis. Moreover, extracts for 
allergen specific immunotherapy are derived from the same source material, possibly 
rendering a costly and lengthy treatment ineffective. 
Manufacturers need to urgently improve the quality of extracts, to ensure consistent content 
and sufficient concentrations. They should consider the possibility of adding recombinant 
allergens to guarantee satisfactory amounts and representation of all relevant allergens, or 
mixing different source material for a better allergen representation. A unified standardization 
and full content declaration should be a minimum.  
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Paper III: Sensitization to horse allergen components is less investigated compared to dogs 
and cats and there is a lack in knowledge about horse allergens. Here we analyze sensitization 
rates to four horse allergens, describe a novel allergen and further characterize full-length Equ 
c 2. We produced two forms of Equ c 2. Although sensitization prevalence to these was low, 
the allergen still is clinically relevant being a lipocalin. The protein family share many 
similarities and cross-reactivity to other lipocalins is not unlikely. Deducing primary 
sensitization source will aid patients in assessing severity of symptoms and avoidance 
measurements. We also identified a new horse allergen, Equ c 7. It shared homology with the 
major cat allergen Fel d 1, which has a sensitization rate over 90%. Likely, Equ c 7 will cause 
an immune response in many cat allergic individuals. In this paper we have further 
characterized a new horse allergen and for the first time described full-length Equ c 2. This 
contributes to a better understanding of horse allergens and could improve diagnostics and 
treatment of allergy to horse. However, probably several horse allergens remain 
uncharacterized and better understanding of the known ones is required. Determining cross-
reactivities and location of allergens on the horse is imperative. Most allergens are discovered 
in horse dander extract, but studies on other species implicates both saliva and urine for 
harboring allergens. Further, as seen in paper IV, the aerodynamic properties of allergens 
differ and could result in altered allergenicity or capability of spreading. Further studies about 
horse allergens and their characteristics are warranted. 
Paper IV: We have quantified two airborne dog allergens using three different sampling 
methods in a controlled manner, reducing contaminants and defining space and volume. 
Detecting particles associated with allergens, revealed that distinct allergens are connected to 
different particle sizes. This can have implications for sensitized individuals, because the size 
of the associated particles can impact the allergenicity of the allergen. Lesser particles can 
travel into the small airways where they can cause a more severe systemic allergic response, 
compared to larger particles. Smaller sized particles have indeed been linked with asthma. 
The study also revealed that different sampling methods displayed opposite accumulation of 
two analyzed allergens. This may reflect their ability to associate to particles with diverse 
characteristics. It is likely that smaller particles have a different dispersion pattern, possibly 
remaining airborne over greater time and space. This is the first study showing that allergen 
molecules have a unique particle size association pattern, which could impact on their clinical 
relevance. Different collection methods yield dominance of certain allergens, showing the 
importance of carefully choosing sampling technique. Distinct allergens hold separate 
aerodynamic properties which should be taken into account when sampling environments and 
when considering avoidance strategies. Further studies should be performed on other 
allergens to determine their airborne characteristics and increasing the cohort for statistical 
soundness.  
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6 FUTURE PERSPECTIVES 
This thesis has contributed to the knowledge of dog and horse allergens, their distribution and 
properties. Further it describes a novel allergen and provides refined characterization of 
others. Importantly, it has highlighted the issues with current diagnostic methods and 
substandard allergen extracts. Yet, there is still much to be done. Improving accuracy of 
allergy diagnosis and treatment success could improve quality of life for the large proportion 
of allergic individuals (243). It could also benefit society as a whole, for example by reducing 
instances of pollen allergic people taking sick leave due to severe symptoms in spring or 
reduce the cost of asthma medication if the underlying allergy is treated.  
In paper I, we explore new diagnostic tools, two microarrays with the capacity to analyze an 
assemblage of allergens compared to standard methods ImmunoCAP and skin prick test. 
They all performed equally, but the microarray methods were able to provide additional 
sensitization information in nearly half of the patients. It is clear that component resolved 
diagnostics improve specificity and have the ability to distinguish between allergen 
components with different clinical implications from the same source. To further refine the 
analysis, more allergen components needs to be identified. Likely, there is an array of 
unknown allergens from the common sources, pets, food, pollen, mold and insect venom. 
From my perspective, pet allergens should be further explored. Cat and dog allergens have 
been thoroughly studied, but less is known about horse allergens. Further studies should be 
conducted on the equine family. If less is known on horse allergen, rare and exotic pets are an 
unmapped domain. Ferrets are kept as pets, and single allergens have been described (244), 
but their allergen profile remain veiled. The same condition applies to small rodents; mice, 
rats and guinea pigs have been described as causing occupational allergies (245, 246), but 
other species from the same order are less studied. Identifying new allergens and producing 
them recombinantly for the purpose of improving allergy diagnostics is an important project. 
As mentioned before, many allergen are similar in structure and most belong to a few 
allergen families. Studies regarding cross-reactivities of these allergens would be the next 
logical step, to deduce primary sensitization targets and potential risk sources. Improving 
production of recombinant allergens can also hopefully reduce the cost, which is another 
factor for the clinician when deciding diagnostic method.  
Paper II highlights the lack of standardization and content cohesion in extracts intended for 
diagnosis by skin prick test. The results clearly shows the discrepancies, not only between 
manufacturers, but also from batch to batch and display how source material affect the 
composition. The extracts needs to improve in quality and content declaration. Spiking the 
extracts with recombinant allergens is one possibility, at least one which would ensure 
enough allergen material for clinical relevance. A problem would still be the uncertainty of 
the remaining uncharacterized content in the extract. Our study showed that the allergen 
proportion in regard to the entire protein concentration was at best a tenth. It would be 
interesting to identify the remaining proteins and to determine if they are relevant from an 
allergen perspective. If these extracts are produced from naturally derived source, it is 
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possible they can contain bacterial, fungal or even other allergenic material from other 
species residing in the fur, such as pollen during season or house dust mites, fleas and lice. It 
could also be just dissolved proteins and peptides or uncharacterized allergens, but the answer 
is still unknown. Performing proteomic analysis and examining the extracts by mass 
spectrometry would be compelling. Another possibility is to produce purely recombinant 
allergen preparations, the risk being the opposite. There might be novel allergens or various 
numbers of isoforms with different allergenic properties, as Equ c 2 displayed in paper III, in 
the extracts and those would be missing in the recombinant mixture. Monosensitized patients 
to those would receive a flawed diagnosis. Identifying new allergens would decrease the risk 
of applying defined recombinant allergens for diagnosis and that is always urgent. A new dog 
allergen was recently described, so clearly the panel is not complete (113). There is more to 
be done in the field of describing allergens. A study similar to ours but on AIT extracts could 
give incentive to improve therapy. Unsuccessful treatment is a common problem and proving 
poor quality of AIT extracts could pave way to a molecular approach to therapy. 
Further, a dog population was analyzed yielding their allergen profiles for six dog allergens. 
The result showed a wide variety of allergen composition and concentration. No correlation 
between breeds or genders was found, except for Can f 5 which is exclusive for male dogs 
being a prostatic protein. Analyzing the two newly described allergens not included in our 
study would be interesting. They have not been detected on dogs, so proving that they indeed 
are dog allergens and present on dogs would render them more valid. Dog saliva has been 
shown to contain a wide variety of allergens including potential novel ones (247), yet new 
allergens are normally detected using immunoblot in dog fur extracts. Our study also show a 
higher concentration of allergens in saliva compared to fur. The prospective of discovering 
new allergens using saliva or urine should be considered. Our study measured allergen 
profiles from a single collection time. Knowledge on whether allergen profiles are stable over 
time is lacking. To address this, dog populations need to be sampled over time to discern 
variation due to seasons, if female dogs are affected by being in heat, differences from puppy 
to adolescent to adult and if ageing induce changes. These are unknown factors and would 
contribute to avoidance advice and possibly in selecting source material for the extracts.  
The identification of a novel allergen, Equ c 7, in paper III is exciting. This opens up a lot of 
possibilities regarding further exploration. The allergen is a homologue to Fel d 1, the major 
cat allergen. A study on cross-reactivity would be interesting including inhibition 
experiments to identify the level of conformational similarities. Further, determining the 
primary sensitization source could aid future diagnosis. Confirming that Equ c 7 is present in 
horse extract or horse source material is also a priority. The horse extract in Sweden has been 
removed from allergen specific immunotherapy, due to unsatisfactory results indicating the 
poor quality of the extracts. This could also affect diagnosis of horse allergy, since the same 
source material can be used to produce both SPT and AIT extracts. A study investigating the 
extracts used for skin prick test for allergen concentration and composition would likely be an 
eye opener. The solution of recombinant allergens are relevant here too. Since horse is less 
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studied compared to dogs and cats, the panel of horse allergens is likely incomplete and 
efforts should be made to identify new allergens. Can f 5 is a major allergen in dogs, possibly 
a homologue exist in horses. The prostatic kallikrein is a conserved protein and humans have 
a homologue (136), investigating stallions could prove prosperous. Horse saliva is another 
allergen candidate, immunoblot should be performed to identify allergen candidates. Cellular 
responses would also be of interest, stimulation of peripheral blood mononuclear cells 
(PBMC) using horse allergen components is a possibility. Our group have developed a 
fluorospot assay to detect activation of rare antigen-specific T-cells by cytokine release in MS 
and cancer. The analysis could be adjusted for application in allergy, correlating cytokine 
profiles from a well characterized patient cohort to an allergen panel. Additionally, the assay 
can be used to monitor a recombinant vaccine experiment in vivo, to compare pro-
inflammatory cytokines to those inducing tolerance.  
The field of aerodynamic properties of allergens is largely unexplored. Previous studies have 
solely analyzed Can f 1. In paper IV we investigate three dog allergens in aerosol samples. 
The logical continuation would be to analyze the remaining dog allergens. Can f 2 is a saliva 
exclusive protein, but could become airborne in exhaled air or in slobber. Due to the fact of 
only having one participating male, Can f 5 was excluded, but in a larger cohort it would be 
interesting to analyze. Can f 6 is present in low amount in fur, but as seen with the other 
allergens, detection was made despite low concentrations. This being a pilot study, with only 
four participating dogs, a larger study would be warranted including more dogs and all dog 
allergens. Identifying the particles associated with the allergens would increase the 
understanding of their properties. Speculation regarding the allergenicity divergence due to 
the size of associated particles is also relevant. An allergen challenge could be performed in 
an animal study using the particle bound allergens. Analysis of bronchoalveolar lavage 
(BAL) and airway responsiveness using a Flexevent (small animal ventilator) would provide 
information whether the different particles affect the development of asthma (248-250).   
The field of allergy is still filled with gaps in knowledge and there is much to be done. 
Especially in improving diagnosis and treatment, which is of critical clinical importance. 
Recombinant allergens is a promising field, with many routes to explore. Our group has 
previously created a recombinant multimer allergen comprising of Can f 1, 2, 4 and 6 (251). 
This has been applied in our inhibition ELISA assays to detect allergen in natural samples. It 
is a promising candidate for a vaccine, and has the ability to induce an IgG response in vivo. 
Further refining this molecule for therapeutics would be interesting. The advantage of the 
multimer being the known concentration and relation of all inherent allergens. However, 
adverse events are problematic when treating allergy. Due to the hypersensitivity, allergen 
exposure can cause severe reactions and worse case anaphylaxis. A solution to minimize the 
risks of AIT is to explore immunomodulatory substances or techniques. For instance, by 
introducing mutations into the recombinant allergen molecules, IgE binding capacity can be 
reduced while maintaining the capability to induce an IgG response (252). Another approach 
is peptide based hypoallergenic vaccines, where the linear T cell epitopes remain intact, while 
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conformational B cell epitopes lose their ability to cross-link IgE (253). Another strategy to 
modulate the allergic immune response is to produce allergen preparations including 
immunomodulatory substances, for example non-digestible oligosaccharides which has been 
shown to modulated the TH2 into a T regulatory response (254). These are all viable routs to 
further explore our vaccine candidate.  
Route of administration is another field to consider. Traditionally AIT is performed either as 
SCIT or SLIT, but efficacy and number of adverse events are inconsistent between studies 
(255). Further the lengthy and frequent treatment discourages patients and compliance can be 
low (256). An option we have considered is intra-lymphatic injections, where the allergen is 
administered straight into the lymph node, thereby bypassing mast cell activation and directly 
introducing the allergen to T cell presentation (257). A further advantage of intra-lymphatic 
injections is the shorter duration and fewer treatment occasions in combination with lower 
allergen dose, increasing the likelihood of patient compliance (258). In summary, continuing 
to explore new allergens and their properties to complete the panel of known proteins capable 
of inducing an immune response feels urgent. Further, utilizing that knowledge will support 
the creation of molecular based diagnostic tools and refine treatment by the aid of 
immunomodulatory techniques and molecules.  
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Allergi är en av våra stora folksjukdomar, där upp till 30% av befolkningen i Sverige är 
drabbad. Symptomen innefattar hösnuva, klåda samt i vissa fall även astma. De mest 
allvarliga fallen kan utlösa livshotande tillstånd. Allergi beror i de flesta fall på ett 
överkänsligt immunförsvar, där celler som ska skydda oss från sjukdomsframkallande ämnen 
inte kan skilja på dessa och harmlösa ämnen och startar en immunreaktion. Dessa ofarliga 
ämnen som har förmågan att initiera allergiska symptom kallas allergen. Allergen är 
proteinmolekyler som förekommer i många kontexter, till exempel hos pälsdjur, i födoämnen, 
hos växtpollen eller i insektsgift. Dessa allergen finns ofta i flertal hos en källa, till exempel 
hund har åtta kända allergen och de flesta hundallergiker reagerar på en eller ett par av dessa 
allergen. Det är därför allergiker kan reagera på en individ av en art, men förbli opåverkad av 
en annan. Vilket allergen man reagerar på är individuellt. Oftast utgörs allergenen av de 
proteiner som har en förmåga att ta sig in i kroppen genom slemhinnan i lungorna eller mag-
tarmkanalen, där de påträffas av immunceller. Hygienhypotesen är en förklaringsmodell för 
uppkomsten av allergi, där en minskad exponering av bakterier i barndomen på grund av 
ökad renlighet leder till ett felprogrammerat immunsystem. Miljöer där man tidigt i livet 
utsätts för bakterier och bakterieprodukter, såsom på bondgårdar eller husdjur i hemmet, har 
påvisat skyddande effekter. Även andra orsaker är kopplade till benägenhet att utveckla 
allergi, såsom gener och ärftlighet, bakteriefloran i tarmen hos nyfödda och RS-virus 
infektion i tidiga år.  
Pälsdjursallergi är en av de mest förekommande typer av allergisk sjukdom. 15-20% av 
svenska invånare reagerar mot hund och runt 5% mot häst. Svårigheten med pälsdjursallergi 
är liksom pollenallergi, den begränsade möjligheten att  undvika exponering av allergenen. 
Studier har påvisat hundallergen både i skolor, på bussar och sjukhus. Pälsdjursallergen är 
ofta lika varandra i uppbyggnad, vilket gör att reaktiviteten ofta visar sig i överkänslighet mot 
flera olika arter. Diagnos ställs av läkare med hjälp av kliniska tester. Den vanligaste metoden 
är pricktest, där en liten droppe extrakt från källan för den misstänkt allergin läggs på 
patientens hud. Därefter punkteras huden och irritationen som uppkommer lokalt mäts i 
diameter som mått på överkänslighet. Den andra rutinmässigt förekommande analysen är 
mätning av en speciell typ av patientens antikroppar i serum från blodet, IgE, som reagerar 
mot allergenet. Vanligtvis sker detta med analyssystemet ImmunoCAP. Finns det en ökad 
mängd IgE antikroppar som är specifikt riktade mot allergenet kallas det sensibilisering. 
Dock är allergi svårdiagnostiserat och det krävs en läkares utlåtande för att konstatera 
sjukdom. Metoden båda dessa analyser grundar sig på, innefattar extrakt producerat av 
naturligt material från allergenkällan, där alla allergen från arten bör ingå. För hund innebär 
det att extraktet är gjort på en stor mängd insamlat hundhår eller mjäll och hudceller, från en 
blandad population hundar, där allergenen utvunnits genom kemiska metoder. 
Extraktionsmetoderna kan dock skada allergenen och omfördela balansen inbördes mellan 
dessa. Vissa allergen finns utöver det bara i saliv eller urin, vilket gör sannorliheten liten för 
att dessa finns representerade i extrakten. Det innebär att tillförlitligheten hos metoderna 
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varierar beroende på kvaliteten på extrakten och att beroende på vilket allergen du är allergisk 
mot, kan testet vara felvisade. Dessa extrakt används även för behandling av allergi med 
allergivaccination, s.k. allergen specifik immunoterapi. Genom att långsamt vänja kroppen 
vid låga doser allergen och sedemera öka dessa kan tolerans uppnås. Denna behandling är 
utdragen, minst 2-3 års behandlingstid samt mellan 80-100 injektioner med allergenextakt, 
därutöver kostsam. På grund av extraktens varierande kvalitet och patientens egen 
överkänslighetsprofil, är behandlingen inte alltid lyckosam och förfinade metoder efterfrågas. 
I delarbete I jämförs två nyare diagnostikinstrument med de tidigare nämnda rutinmetoderna 
pricktest och ImmunoCAP, samt mot läkarens diagnos. De två nya metoderna har en panel av 
allergen där man simultant kan testa sensibilisering mot en mängd olika allergen och 
allergenextrakt. Fördelen är att det krävs mycket mindre serum samt att man kan analysera 
fler allergen jämfört med konventionella metoder. Detta är av särskild vikt när patienten 
reagerar mot allergen som är strukturmässigt lika mellan olika arter. Är patienten 
sensibiliserad mot ett hundallergen som är närbesläktat med ett hästallergen kan denne få 
allergiska symptom av både hund och häst. Sådan information är viktig vid behandling och 
för förebyggande åtgärder. I denna studie deltog 71 barn med ihållande astma, bland vilka 
allergi mot 10 vanliga allergenkällor undersöktes. Totalt 75% av barnen reagerade mot något 
av de 10 utvalda allergenen och nästan hälften av alla vara överkänsliga mot tre eller fler 
allergenkällor. Resultaten visade att alla fyra metoderna var likvärdiga i noggrannhet och 
samstämmiga i 90-92% av alla analyser. Utöver det erhölls ny information om ytterligare 
allergier i 47% av alla fallen vid paneltesterna. Panelerna bidrar således med mer nogrannhet 
och har inte sämre träffsäkerhet eller känslighet jämfört med nuvarande metoder. Majoriten 
av barnen med astma hade underliggande allergi, vilket föranleder att barn av denna kategori 
bör utredas för allergi rutinmässigt.  
Delarbete II undersökte innehållet i hundextrakt som används i rutinvården för pricktest vid 
allergidiagnostik. Extrakten består av naturligt material och deras innehåll är undermåligt 
beskrivna. Vi har tagit fram analysmetoder för att mäta sex olika hundallergen i extrakten och 
från hundars päls och saliv. Resltaten visade att de fem olika testade extrakten varierade 
mycket, både innehållsmässigt och avseende allergenens inbördes proportioner. Vissa 
allergen detekterades endast i mycket små mängder, där det är tveksamt ifall dessa skulle ge 
utslag i ett pricktest. Vi jämförde också extrakt från olika källor, och de skiljde sig markant 
mellan hår, hudceller och mjäll. För att undersöka de kliniska aspekterna, testade vi 
immuncellers reaktionsförmåga mot dessa extrakt från tre hundallergiker. Flertalet extrakt 
lyckades inte skapa en immunologisk reaktion, trots att patienterna hade allergiska symtom 
vid kontakt med hundar. Detta är oroande, då patientsäkerheten kan hotas p.g.a. den skiftande 
kvaliteten på extrakten . Trots detta används de rutinmässigt vid allergidiagnostik. Då 
extrakten baseras på naturliga råvaror analyserades också etthundratjugo hundar för 
allergenförekomst. Dessa varierade också ansenligt, där skillnaden på individnivå var större 
än mellan rastillhörighet. Saliven hade en högre mängd allergen jämfört med päls och 
intressant nog återfanns allergenet Can f 4 i störst kvantitet. I extrakten var i motsats Can f 3 
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högst i koncentration. Detta kan bero på hur extrakten produceras, där vissa allergen kanske 
delvis sönderfaller. Dock återspeglar extrakten inte den naturliga fördelningen av allergen, 
vilket även kan påverka diagnostiken. Risken är att patienter får en felaktig diagnos och att 
sjukdomstillstånd inte upptäcks. Samma typ av extrakt används även vid behandling av 
allergi, där effekten riskerar att utebli och patienten genomgår en utdragen ineffektiv terapi.  
Delarbete III fokuserade på hästallergen och hur många allergiker som reagerar på dessa. 
Allergi mot häst är betydligt mindre studerat än allergi mot katt och hund, trots att hästar och 
hästsport är en vanlig fritidssysselsättning i vårt samhälle. Fem hästallergen finns idag 
identifierade, dessvärre är vissa inte så väl undersökta. Vi har med DNA-teknik producerat 
allergenet Equ c 2, som tidigare inte varit komplett beskrivet. Två former av detta allergen 
togs fram, dels från urhästen Przewalskis häst samt från nutida häst. Dessa två former är 
identiska till 2/3, men skiljer sig åt tillräckligt för att ifrågasätta om de två studerade formerna 
kan sägas vara samma allergen. Vi undersökte sera från misstänkt allergiska individer och 15-
16% av serana reagerade mot Equ c 2 och den stora majoriteten av dessa svarade på båda 
formerna, vilket indikerar stor likhet dem emellan. Utöver detta upptäcktes ett nytt allergen, 
kallat Equ c 7. Detta allergen uppvisade samstämmighet med ett av kattens allergen Fel d 1, 
sannorlikt orsakar det symptom hos både häst- och kattallergiker. Mer än en tredjedel av de 
undersökta serana reagerade mot detta allergen, vilket antyder att det kan ha en viktig roll 
inom diagnosik och behandling. Huvudallegenet mot häst, Equ c 1, analyserades också och 
påvisade att en stor andel är känsliga mot detta allergen, dessutom  att en övervägande andel 
är sensibliserade mot Equ c 4, ett allergen som har tvättmedelslika egenskaper (löddrar samt 
tar bort ytspänningen) och återfinns i hästars svett. Den här artikeln bidrar med en utökad 
kunskap om hästars allergen och hur personer som är överkänsliga mot häst reagerar mot de 
enskilda allergenen. Denna kunskap kan förhoppningsvis bidra till en nogrannare diagnosik 
och mer träffsäker behandling. 
Luftburna allergens egenskaper studerades i delarbete IV. Hundens allergen Can f 1 är det 
enda allergen som undersökts tidigare för aerodynamiska attribut, d.v.s. hur allergenet sprids 
på luftburna partiklar. I denna studie analyserades tre allergen för första gången, Can f 1, Can 
f 3 och Can f 4. Can f 3 detekteras tyvärr inte i luftproverna, däremot de övriga två. Ett av 
analysinstrumenten detekterade storleken på partiklar som allergen sammankopplas med. Can 
f 1 återfanns på större partiklar inom spektrat, medan Can f 4 hittades på partiklar utav alla 
storlekar. Informationen är vikteg eftersom mindre partiklar kan tränga längre ner i lungorna 
och på så sätt ha större möjligheter att initiera en inflammation. Mindre partiklar associeras 
också med astma i större utstäckning. Prover togs även från luftpumpar, där Can f 1 
detekteras i högre utstäckning än Can f 4. Tvärtom var det i insamlat material från en 
luftcentrifug där proportionen Can f 4 var större. Sammantaget visar detta att olika 
insamlingsmetoder  har varierande förmåga att detektera lufrburet allergen i materialet. 
Därför bör tonviken vid val av metod, läggas på frågeställningen. Olika allegen har särskilda 
aerodynamiska egenskaper och detta bör vägas in i hur hälsovådliga dessa är för allergiker, 
hur man exponeras för dessa och riskerna med att utsättas för dem. 
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Sammanfattningsvis lämnar diagnostiken av allergi mycket att önska. Extrakten som testerna 
vanligtvis baseras på är undermåliga och med dessa som underlag riskerar fel diagnos att 
ställas. Därför är nyare analysinstrument intressanta då de kan detektera många fler allergen 
simultant och mer specifikt. Även mer kunskap om okända allergen och allergens luftburna 
egenskaper är viktiga för att kunna förbättra diagnos, behandling och prevention. 
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